SCHEMBL3409105

SCHEMBL3409105

Nc1nc(-c2ccccc2)nc2[nH]nc(Nc3ccc(Cl)cc3)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.52
PDE5A O76074 1/20 0.52
TRPA1 O75762 1/20 0.46
GAA P10253 2/20 0.44
MAPT P10636 2/20 0.44
TP53 P04637 2/20 0.44
POLB P06746 1/20 0.44
DPP4 P27487 1/20 0.43
AGPAT2 O15120 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NR1H2 P55055 1/20 0.42
NR1H3 Q13133 1/20 0.42
GFER P55789 1/20 0.42
ADK P55263 1/20 0.41
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3602136 0.91 ABCG2 (0.47) ABCG2PDE5AGAAMAPTTP53
SCHEMBL3409557 0.88 PTGS2 (0.47) ABCG2PDE5ATRPA1GAAMAPT
SCHEMBL3413002 0.88 ABCG2 (0.54) ABCG2PDE5AGAAMAPTTP53
SCHEMBL3600310 0.88 ABCG2 (0.52) ABCG2PDE5AGAAMAPTTP53
SCHEMBL3415833 0.88 MAPT (0.52) ABCG2MAPTTP53DPP4MEN1
SCHEMBL16492396 0.87 ABCG2 (0.55) ABCG2PDE5AGAAMAPTDPP4
SCHEMBL14861915 0.85 ABCG2 (0.56) ABCG2DPP4MEN1KMT2ARAB9A
SCHEMBL14861582 0.84 LMNA (0.48) ABCG2TRPA1MAPTHPGD
SCHEMBL29648256 0.84 LMNA (0.48) ABCG2TRPA1MAPTHPGD
SCHEMBL19719713 0.83 ABCG2 (0.46) ABCG2MAPTTP53DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962634-B2 4-amino-3-arylamino-6-arylpyrazolo[3,4-d) pyrimidine derivatives, methods for their preparation and their use as antiviral agents DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2015-02-24 US claimed
EP-2049540-B1 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS DRITTE PATENTPORTFOLIO BETEILI (DE) 2010-12-22 EP claimed
US-20100010018-A1 4-Amino-3-Arylamino-6-Arylpyrazolo[3,4-D) Pyrimidine Derivatives, Methods for their Preparation and their Use as Antiviral Agents DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2010-01-14 US claimed
EP-2049540-A1 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co.KG (DE) 2009-04-22 EP claimed
WO-2007147401-A1 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO.KG (DE) 2007-12-27 WO claimed
EP-2766367-B1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for the treatment of viral infections, in particular picornavirus infections SCANDION ONCOLOGY AS (DK) 2022-05-18 EP disclosed
EP-2766367-B1 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for the treatment of viral infections, in particular picornavirus infections SCANDION ONCOLOGY AS (DK) 2022-05-18 EP disclosed
US-9790225-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2017-10-17 US disclosed
US-9790225-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2017-10-17 US disclosed
US-9790225-B2 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances SCANDION ONCOLOGY A/S (DK) 2017-10-17 US disclosed
US-9382286-B2 Treatment of EBV and KHSV infection and associated abnormal cellular proliferation EMORY UNIVERSITY (US) 2016-07-05 US disclosed
US-8962634-B2 4-amino-3-arylamino-6-arylpyrazolo[3,4-d) pyrimidine derivatives, methods for their preparation and their use as antiviral agents DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2015-02-24 US disclosed
WO-2013053942-A1 4-AMINO-3-PHENYLAMINO-6-PHENYLPYRAZOLO[3,4-D] PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS ANTIVIRAL ACTIVE SUBSTANCES DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2013-04-18 WO disclosed
EP-2049540-B1 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS DRITTE PATENTPORTFOLIO BETEILI (DE) 2010-12-22 EP disclosed
US-20100168052-A1 Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation PHARMASSET, INC. (US) 2010-07-01 US disclosed
US-20100010018-A1 4-Amino-3-Arylamino-6-Arylpyrazolo[3,4-D) Pyrimidine Derivatives, Methods for their Preparation and their Use as Antiviral Agents DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) 2010-01-14 US disclosed
US-7638502-B2 Treatment of EBV and KHSV infection and associated abnormal cellular proliferation PHARMASSET, INC. (US) 2009-12-29 US disclosed
US-20070197462-A1 Treatment of EBV and KHSV infection and associated abnormal cellular proliferation PHARMASSET, INC. (US) 2007-08-23 US disclosed
US-7211570-B2 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") PHARMASSET, INC. (US) 2007-05-01 US disclosed
US-20030176392-A1 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") EMORY UNIVERSITY 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176392-A1 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") UMPS, UNG, TYMP ABCG2 784/4885PDE5A 1625/4885TRPA1 4705/4885
US-20070197462-A1 Treatment of EBV and KHSV infection and associated abnormal cellular proliferation UMPS, ENTPD5, TK1 ABCG2 1860/4885PDE5A 3085/4885TRPA1 4781/4885
US-20100168052-A1 Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation UMPS, ENTPD5, TK1 ABCG2 1860/4885PDE5A 3085/4885TRPA1 4781/4885
US-20100010018-A1 4-Amino-3-Arylamino-6-Arylpyrazolo[3,4-D) Pyrimidine Derivatives, Methods for their Preparation and their Use as Antiviral Agents PNP, TYMP, EIF2AK2 ABCG2 136/4885PDE5A 1092/4885TRPA1 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.